Annexon (NASDAQ:ANNX) EVP Sells $26,979.00 in Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Dean Richard Artis sold 5,290 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.10, for a total transaction of $26,979.00. Following the transaction, the executive vice president directly owned 123,487 shares of the company’s stock, valued at approximately $629,783.70. This represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Annexon Stock Performance

Shares of Annexon stock opened at $4.90 on Monday. Annexon, Inc. has a 1 year low of $1.28 and a 1 year high of $7.18. The firm’s 50-day simple moving average is $5.58 and its 200-day simple moving average is $3.96. The firm has a market cap of $586.19 million, a PE ratio of -3.48 and a beta of 1.17.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ANNX. Wealth Enhancement Advisory Services LLC grew its stake in shares of Annexon by 13.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 19,553 shares of the company’s stock worth $100,000 after purchasing an additional 2,348 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Annexon by 65.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after purchasing an additional 2,785 shares during the period. Susquehanna Portfolio Strategies LLC grew its position in Annexon by 0.8% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 356,619 shares of the company’s stock valued at $1,790,000 after buying an additional 2,875 shares in the last quarter. ProShare Advisors LLC grew its position in Annexon by 21.7% in the 4th quarter. ProShare Advisors LLC now owns 24,698 shares of the company’s stock valued at $124,000 after buying an additional 4,410 shares in the last quarter. Finally, Citizens Financial Group Inc. RI increased its stake in Annexon by 14.3% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock valued at $122,000 after buying an additional 5,000 shares during the period.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ANNX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Chardan Capital started coverage on shares of Annexon in a report on Tuesday, December 23rd. They issued a “buy” rating and a $16.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, January 21st. Finally, Wells Fargo & Company raised their price target on shares of Annexon from $14.00 to $27.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Key Stories Impacting Annexon

Here are the key news stories impacting Annexon this week:

• Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
• Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 – Overdorf
• Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 – Yednock
• Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 – Artis
• Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 – Lew
• Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 – Dananberg

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.